Pure Global

Devyser RHD 8-R060-78 8-R060-390 - Foetal blood group genotyping IVD, kit, nucleic acid technique (NAT) - ARTG 481205

Access comprehensive regulatory information for Devyser RHD 8-R060-78 8-R060-390 - Foetal blood group genotyping IVD, kit, nucleic acid technique (NAT) in the Australia medical device market through Pure Global AI's free TGA ARTG database. This Class III is registered under ARTG number 481205 and sponsored by Abacus dx Pty Ltd, manufactured by Devyser AB in Sweden. The device registration started on February 28, 2025.

This page provides complete registration details including sponsor information, manufacturer details, and regulatory compliance data from the official Australia TGA ARTG medical device database. Pure Global AI offers free access to Australia's complete medical device registry with 131,000+ devices, helping global MedTech companies navigate TGA regulations efficiently.

Free Database
Powered by Pure Global AI
TGA ARTG Official Data
Class III
ARTG 481205
Class III
Devyser RHD 8-R060-78 8-R060-390 - Foetal blood group genotyping IVD, kit, nucleic acid technique (NAT)
ARTG ID: 481205
Good Name: Abacus dx Pty Ltd - Devyser RHD 8-R060-78 8-R060-390 - Foetal blood group genotyping IVD, kit, nucleic acid technique (NAT)
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Intended Purpose

Devyser RHD is a qualitative real-time PCR test for the detection of RHD present in cell-free DNA (cfDNA) in human plasma. The device is an in vitro diagnostic product intended to determine RhD feto-maternal blood group incompatibility in plasma obtained from pregnant women who have been determined as RhD negative.

Device Classification
Risk Class
Class III
Product Type
IVD
ARTG Category
IVD
Registration Information
ARTG ID
481205
Start Date
February 28, 2025
Effective Date
February 28, 2025
Manufacturer
Country
Sweden
Address
Branningevagen 12, Arsta, 120 54